These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25261505)

  • 1. Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.
    Birnbaum G; Iverson J
    Neurology; 2014 Oct; 83(18):1610-2. PubMed ID: 25261505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR; Bienen EJ; Blight AR
    Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.
    Thaera GM; Wingerchuk DM; Carter JL
    Mult Scler Relat Disord; 2014 Jan; 3(1):107-9. PubMed ID: 25877980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
    Dunn J; Blight A
    Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
    Panicucci E; Cohen M; Bourg V; Rocher F; Thomas P; Lebrun C
    Mult Scler; 2019 Apr; 25(4):618-621. PubMed ID: 30375922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
    Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
    Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalfampridine: a new agent for symptomatic management of multiple sclerosis.
    McDonald S; Clements JN
    Am J Health Syst Pharm; 2011 Dec; 68(24):2335-40. PubMed ID: 22135060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalfampridine in multiple sclerosis.
    Goodman AD; Hyland M
    Drugs Today (Barc); 2010 Sep; 46(9):635-9. PubMed ID: 20967295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of dalfampridine in patients with multiple sclerosis.
    Ruck T; Bittner S; Simon OJ; Göbel K; Wiendl H; Schilling M; Meuth SG
    J Neurol Sci; 2014 Feb; 337(1-2):18-24. PubMed ID: 24290498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recurrence and de novo trigeminal neuralgia induced by fampridine].
    Montcuquet A; Magy L
    Rev Neurol (Paris); 2015 Feb; 171(2):198-9. PubMed ID: 25555847
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
    Egeberg MD; Oh CY; Bainbridge JL
    Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
    Pikoulas TE; Fuller MA
    Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after percutaneous surgery for patients with multiple sclerosis-related trigeminal neuralgia.
    Mallory GW; Atkinson JL; Stien KJ; Keegan BM; Pollock BE
    Neurosurgery; 2012 Sep; 71(3):581-6; discussion 586. PubMed ID: 22592326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
    Kantor D; Chancellor MB; Snell CW; Henney HR; Rabinowicz AL
    Postgrad Med; 2015 Mar; 127(2):218-22. PubMed ID: 25560174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
    Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
    Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR; Henney HR; Cohen R
    Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma knife radiosurgery for multiple sclerosis-related trigeminal neuralgia.
    Zorro O; Lobato-Polo J; Kano H; Flickinger JC; Lunsford LD; Kondziolka D
    Neurology; 2009 Oct; 73(14):1149-54. PubMed ID: 19805732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
    Limone BL; Sidovar MF; Coleman CI
    Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
    Lugaresi A
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Status epilepticus associated with dalfampridine in a patient with multiple sclerosis.
    de Gusmao CM; Ortega MR; Wallace DM
    J Neuropsychiatry Clin Neurosci; 2012; 24(4):E47-8. PubMed ID: 23224484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.